FDA Approves Curium's BEXLUTRY for Gastroenteropancreatic Neuroendocrine Tumors

Key Facts

In a move that expands therapeutic options within the oncology sector, the U.S. Food and Drug Administration (FDA) has approved Curium's New Drug Application for BEXLUTRY. This treatment, a lutetium Lu 177 dotatate injection, is indicated for adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The approval marks a significant regulatory milestone for Curium, specifically targeting tumors in the foregut, midgut, and hindgut.

According to technical reports, BEXLUTRY was approved as a radioligand equivalent through the FDA’s 505(b)(2) pathway, supported by data demonstrating a similar biological profile to existing radiopharmaceutical therapies. This development is strategically important as GEP-NETs account for approximately 60-70% of all neuroendocrine tumors, positioning the company to address a substantial portion of the market for specialized cancer treatments.

As of the market close on September 14, 2026, authoritative price data for the instrument is unavailable, requiring a qualitative outlook on the healthcare sector's response. Investors should monitor future commercial rollout updates for BEXLUTRY. There are no major upcoming catalysts in the immediate economic calendar specifically linked to this pharmaceutical development.